Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Jan 3;12:810295. doi: 10.3389/fphar.2021.810295

Corrigendum: Neuroprotective Effects of the Anti-Cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis

Ji-Ning Jia 1,2,3,4,, Xi-Xi Yin 5,, Qin Li 1,2,3,4, Qi-Wen Guan 1,2,3,4, Nan Yang 1,2,3,4, Kang-Ni Chen 1,2,3,4, Hong-Hao Zhou 1,2,3,4, Xiao-Yuan Mao 1,2,3,4,*
PMCID: PMC8762335  PMID: 35046829

In the original article, there was a mistake in Figure 5F and Figure 6B as published. Due to our carelessness in the process of rearranging these figures, the image in the “Era + Fer-1” group within Figure 5F and the image in the “Lap” group within Figure 6B were uploaded with mistakes. The corrected Figure 5 and Figure 6 appears below.

FIGURE 5.

FIGURE 5

Lapatinib prevents Glu- or erastin-induced neuronal death possibly by suppressing ferroptosis (A–D) Detection of lipid ROS, 4-HNE and MDA content in the glutamate (Glu)- or erastin (Era)-induced HT22 cell death model following lapatinib (Lap) (10 μM) and ferrostatin-1 (Fer-1) (12.5 μM) pretreatment for 2 h (E) RT-qPCR analysis of PTGS2 mRNA expression pretreated with or without Lap (10 μM) and Fer-1 (12.5 μM) in HT22 cells induced by Glu or Era (F,G) Comparisons of combination of Lap and ferroptosis inhibitors and Lap alone in HT22 cells following Glu or Era challenge when pretreatment with Lap (10 μM), Fer-1 (12.5 μM), liproxstatin-1 (Lip-1) (1 μM) and deferoxamine (DFO) (50 μM) pretreatment for 2 h. Scale bar: 200 μm. All results were presented as the mean ± SEM from three independent experiments, ns indicates no statistical significance. **p < 0.01 and ***p < 0.001.

FIGURE 6.

FIGURE 6

Lapatinib inhibits neuronal ferroptosis by blocking the downregulation of GPX4 (A) Effects of lapatinib (Lap) or ferrostatin-1 (Fer-1) on the expressions of ferroptosis-related proteins including glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), 5-Lipoxygenase (5-LOX) or acyl-CoA synthetase 4 (ACSL4) in HT22 cell death model induced by glutamate (Glu) or erastin (Era). The value below the band is obtained via ImageJ analysis (B) Immunofluorescence analysis of GPX4 expression after pretreatment for 2 h with Lap (10 μM), followed by exposure to Glu or Era for another 8 h in HT22 cells. Scale bar: 50 μm (C) GSH level was assessed following Lap (10 μM) pretreatment for 2 h (D,E) Effects of GPX4 inhibition by ras-selective lethal small molecule 3 (RSL3) (1 nM) on the neuroprotection of Lap (10 μM) against Glu- or erastin-induced cell death in HT22 cells. Scale bar: 200 μm. All results were shown as the mean ± SEM from three independent experiments, ns means the difference is not statistically significant, ***p < 0.001.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES